The Observer featured Constructive Bio in coverage of environmental challenges in peptide drug manufacturing, highlighting the company’s fermentation-based approach as…
SynBioBeta featured an interview with Constructive Bio founder and CSO Professor Jason Chin on expanded genetic codes and novel polymer…
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio entered a collaboration with the Ellison Institute of Technology’s Generative Biology Institute (GBI) in Oxford, combining synthetic genome…
Constructive Bio hosted the Cambridge iGEM 2025 team at The Recodery for a technical discussion on synthetic biology research, as…
Constructive Bio is contributing its large-scale genome assembly platform to an ARIA-funded collaboration with Camena Bioscience and the Max-Planck Institute…
The New York Times covered the creation of Syn57, an E. coli strain with a 57-codon synthetic genome — the…
Constructive Bio’s founder and CSO, Professor Jason Chin, was reappointed as a Non-Executive Director on the UK Department for Science,…
Constructive Bio expanded to new headquarters in the Cambridge Biomedical Cluster, taking all lab space at Gen Two in Whittlesford…
The Financial Times profiled Constructive Bio’s work in synthetic genomics and genetic code rewriting, covering the Cambridge company’s approach to…
Engineering the future of biology with revolutionary genome synthesis and expanded genetic code technology.
QUICK LINKS
JOIN OUR NEWSLETTER
© 2026 Constructive Bio. All rights reserved.